Merck seeks China and US approval of TGCT drug after Phase III success
Merck KGaA (Merck) is filing for global regulatory approvals of its CSF-1R inhibitor pimicotinib after it met the primary and all …
Post
-
-
Scynexis resumes dosing in Phase III MARIO study after lengthy delay
Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a 19-month …
-
FDA grants RMAT designation to AbelZeta’s CAR-T therapy
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta Pharma’s autologous bi-specific …
-
4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules
In the race to decarbonize the global economy, advanced materials are no longer a luxury - they're a necessity. The …
-
How 3PL providers are gearing up for the wave of cell and gene therapies
The global cell and gene therapy (CGT) market is expanding at a rapid rate, and will be worth $76bn by …
-
CDC drops Covid-19 vaccine for healthy children and pregnant women
The US Centers for Disease Control and Prevention (CDC) is no longer recommending Covid-19 vaccines to healthy children and pregnant …
-
GlycoEra secures $130m to progress IgG4-targeted protein degrader
Biotechnology company GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support the progression of its lead …
-
Biogen and City Therapeutics to develop RNAi therapy
Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging tissue-enhanced delivery technologies, the …
-
How the cell and gene therapy market is taking shape
Cell and gene therapy (C>) represents a major advance in medical treatments by directly targeting the root causes of diseases …
-
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout
Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big …
-
Capitalising on UK’s goal to become a world-leading clinical trial destination
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following …
-
GSK makes new drug submission for depemokimab in Canada
GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific conditions. The …
-
What’s been agreed at this year’s World Health Assembly?
With the 78th World Health Assembly ending today, all eyes have been on this year’s World Health Organization (WHO) member’s …
-
Lupin partners SteinCares to commercialise biosimilar in LATAM
Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American markets, excluding …
-
FDA to review Otsuka’s sibeprenlimab application for IgAN
The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for sibeprenlimab for review. The monoclonal …
